NCT06656221
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
- Locations
-
Not specified
Clinical trial condition
Lymphoma, Non-Hodgkin
Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.
2,774 public trials
698 recruiting studies
Lymphoma, Non-Hodgkin trial results
Not Yet Recruiting
Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma
NCT06671717
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
- Locations
-
- Peking University, Institute of Hematolgoy, Beijing, Beijing, China
Not Yet Recruiting
ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
NCT06646666
- Conditions
- B-cell Non Hodgkin Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- Department of Hematology, Shanghai Institute of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China
Not Yet Recruiting
Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission
NCT06669143
- Conditions
- Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
Not specified
NCT06656234
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- Ruijin Hospital, Shanghai JiaoTong University School of Medicine Shanghai, Shanghai Municipality, China
Not Yet Recruiting
Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma
NCT06652152
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL), Double Expressor Lymphoma, Hemic and Lymphatic Diseases, +10 more
- Locations
-
Not specified
Not Yet Recruiting
Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC Positive
NCT06652139
- Conditions
- Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
Not specified
Not Yet Recruiting
Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study
NCT06651203
- Conditions
- Cutaneous T Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
- Locations
-
Not specified
Not Yet Recruiting
Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
NCT06549335
- Conditions
- Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +8 more
- Locations
-
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, China
Not Yet Recruiting
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
NCT06594432
- Conditions
- Diffuse Large B Cell Lymphoma (DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
- Hematological Department, People's Hospital of Jiangsu Province Nanjing, Jiangsu, China